AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

RECOMMEND Platform Trial

RecruitingPhase 3Ages any - anyAllAustralian and New Zealand Intensive Care Researcโ€ฆ
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The goal of this platform trial is to determine the efficacy, safety and cost-effectiveness of various interventions in patients with acute cardiorespiratory failure requiring extracorporeal membrane oxygenation (ECMO) The main question the platform trial aims to address is to determine the effect of a range of interventions on survival, organ support and resource utilisation to day 28 for hospitalised patients receiving ECMO. Researchers will compare various interventions within multiple platform trial domains to see if the interventions have effects on survival, organ support and resource utilisation for the patient cohort. Participants will be enrolled in accordance with the platform trial's domain structure to answer the research questions.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
PLATFORM INCLUSION CRITERIA: * Patients receiving ECMO * Patients enrolled in the EXCEL Registry - NCT03793257 PLATFORM EXCLUSION CRITERIA: * Treating clinician regards death as imminent and inevitable * Treating clinician determines it is not in the patient's best interests RBC TRANSFUSION DOMAIN INCLUSION CRITERIA: โ€ข Aged 18 years or older RBC TRANSFUSION DOMAIN EXCLUSION CRITERIA: * Contraindication to RBC transfusion (including known patient preference) * Limitations of care put in place either through patient wishes or the treating medical teams. * Participant has already received ECMO \>12 hours. The start of ECMO is defined as the time of initiation of extracorporeal blood flow unless ECMO was initiated during a surgical intervention in which case the start of ECMO is defined as the arrival time into the initial ICU (post-surgery) * The treating physician anticipates that ECMO treatment will cease before the end of tomorrow * The treating physician deems the study is not in the patient's best interest * The treating physician has concern regarding patient ability to tolerate restrictive or liberal transfusion trigger thresholds * Actively listed for a solid organ transplant and has not yet received one * Suspected or confirmed to be pregnant * Previous ECMO treatment during the same hospital admission
๐Ÿ’Š

What it tests

  • Liberal RBC Transfusion
  • Restrictive RBC Transfusion
๐Ÿ“

Where

3 sites
Royal Prince Alfred Hospital
Camperdown, Australia
St. Vincent's Hospital Sydney
Sydney, Australia
The Alfred Hospital
Melbourne, Australia
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy